Literature DB >> 15253471

Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature.

Chiao-Li Ke1, Cheng-Fang Yen, Cheng-Chung Chen, Shang-Ju Yang, Weilun Chung, Ming-Jen Yang.   

Abstract

Treatment-emergent obsessive-compulsive symptoms (OCSs) have raised concern since the widespread introduction of serotonin-dopamine antagonists (SDAs) for the treatment of schizophrenia. Further investigations of SDA-emergent OCSs and their response to anti-obsessional agents will be beneficial for clinicians in helping patients who suffer from this problem. We present three cases of schizophrenia in which distressing OCSs occurred during clozapine or risperidone treatment. OCSs were assessed consecutively using the Yale-Brown Obsessive-Compulsive Scale. The OCSs of these three patients were responsive to anti-obsessional agents, including fluvoxamine, clomipramine, and paroxetine. We also review the current literature and discuss the possible pathophysiology and psychopathology of SDA-emergent OCSs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15253471     DOI: 10.1016/S1607-551X(09)70121-4

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  3 in total

Review 1.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

2.  Drug Induced Obsessive Compulsive Disorder in Schizophrenia.

Authors:  R K Saini; V Pande
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications.

Authors:  Stefano Pallanti; Giacomo Grassi; Elisa Dinah Sarrecchia; Andrea Cantisani; Matteo Pellegrini
Journal:  Front Psychiatry       Date:  2011-12-21       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.